Last reviewed · How we verify

ASC40 — Competitive Intelligence Brief

ASC40 (ASC40) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HBV capsid assembly inhibitor. Area: Virology / Hepatology.

phase 3 HBV capsid assembly inhibitor HBV core antigen (HBcAg) Virology / Hepatology Small molecule Live · refreshed every 30 min

Target snapshot

ASC40 (ASC40) — Ascletis Pharmaceuticals Co., Ltd.. ASC40 is a hepatitis B virus (HBV) capsid assembly modulator that disrupts viral particle formation.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ASC40 TARGET ASC40 Ascletis Pharmaceuticals Co., Ltd. phase 3 HBV capsid assembly inhibitor HBV core antigen (HBcAg)
ASC40 tablets ASC40 tablets Ascletis Pharmaceuticals Co., Ltd. phase 3 HBV capsid assembly inhibitor HBV core antigen (capsid assembly)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HBV capsid assembly inhibitor class)

  1. Ascletis Pharmaceuticals Co., Ltd. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ASC40 — Competitive Intelligence Brief. https://druglandscape.com/ci/asc40. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: